Egis consolidated Q4 net profit drops 27% yr/yr
Hungarian drug maker Egis, majority-owned by France's Servier, had consolidated net profit of HUF 2.06bn in the fourth quarter of its business year ended September 30, down 27.1% yr/yr from HUF 2.8bn in the same period a year earlier, the company's IFRS report published on Wednesday evening shows.
Fourth-quarter net profit was 48% below the estimate by analysts polled by Portfolio.hu. Sales rose 2% to HUF 33.07bn in Q4. Sales in Russia, Egis's biggest export market, were up 7% at €27.1m.
Excluding the effect of advance purchases made by Russian partners from the last quarter of the previous business year, sales in the fourth quarter were up 14%. Cost of sales rose 5% in the fourth quarter.
Consolidated operating profit declined 56% to HUF 2.02bn. Pre-tax profit dropped 18% to HUF 2.719bn. For its full 2010/2011 business year, Egis's after-tax profit was down 19% yr/yr at HUF 13.6bn.
Full-year EPS came to HUF 1,745. Excluding one-off items, after-tax profit was down 9% yr/yr. Sales rose 8% to HUF 128.939bn as domestic sales increased 7% to HUF 34.9bn and export sales climbed 10% to €345.5m.
Sales to Russia and other CIS states rose 9% to €150.9m. Sales in Eastern Europe rose 3% to €134.2m. Egis' cost of sales rose 5% for the full year. Operating profit was down 5%, totaling HUF 16.3bn. Pre-tax profit came to HUF 15.676bn for the full year. Net assets were up 8% at HUF 161.6bn.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.